STOCKHOLM – November 03, 2026 -- The U.S. Patent and Trademark Office has granted Moberg Pharma a patent on an improved dosing regimen for MOB-015, its topical onychomycosis drug, with a projected expiry in December 2041. The U.S. is the first market to grant a patent on the new dosing.

Stockholm – November 03, 2026 -- Sobi (STO: SOBI) will present six abstracts on two late-stage gout assets, pozdeutinurad (AR882) and nanoencapsulated sirolimus plus pegadricase (NASP), at ACR Convergence 2026, the American College of Rheumatology annual meeting, in Orlando, Florida, on 6–11 November 2026.

PLYMOUTH MEETING – November 03, 2026 -- INOVIO (NASDAQ: INO) will present its INO-D001 program for Hemophilia A at the World Federation of Hemophilia New Technology & Gene Therapy (NTGT) Workshop in Montreal on Thursday, Nov. 12, extending its DNA medicine work beyond HPV-related diseases, cancer and infectious diseases.

MIAMI – November 02, 2026 -- Brand and condition websites account for just 17% of AI-answer citations on average, according to PharmaForceIQ audits behind the launch of Share of Answer, a new module in its Optichannel 360 platform for biopharma companies.

Audits find retired webpages and superseded FDA labeling in AI answers

The audits identified citations to hundreds of retired webpages. In one analysis, AI-generated responses quoted superseded FDA-approved labeling in nearly 250 answers.

STOCKHOLM – November 02, 2026 -- BioArctic AB will keep the full USD 30 million upfront payment from Novartis Pharma AG after Novartis terminated their Option, Collaboration and License Agreement, the Nasdaq Stockholm-listed company (BIOA B) announced.

SAN DIEGO – November 02, 2026 -- Neurocrine Biosciences (Nasdaq: NBIX) grew third-quarter 2026 revenue 41% year over year to $1.1 billion, up from $795 million, and raised its full-year INGREZZA net sales guidance to $2.9 billion to $2.925 billion.

The prior INGREZZA range was $2.825 billion to $2.875 billion. Net product sales topped $1 billion for the first time, according to the company.

JERSEY CITY – November 02, 2026 -- ABVC BioPharma (NASDAQ: ABVC) has closed a private placement of original issue discount senior convertible promissory notes that generated approximately $3.39 million in gross proceeds, before placement agent fees and offering expenses, WallachBeth Capital LLC announced.

Notes carry $4.1 million principal and a June 2027 maturity

The 17.5% OID Notes have an aggregate principal amount of $4,106,060 and mature on June 30, 2027. Investors in the securities purchase agreement are institutional and other accredited investors.

BOULDER – November 02, 2026 -- Edgewise Therapeutics (Nasdaq: EWTX) granted inducement stock options on 17,250 shares and restricted stock units covering 8,626 shares to two new non-executive employees on October 30, 2026.

Options carry a $38.90 exercise price set at the grant-date close

Each option has an exercise price of $38.90 per share, equal to Edgewise's closing share price on the grant date. The awards were made under the company's 2024 Inducement Equity Incentive Plan.

NEW YORK – November 02, 2026 -- Nuvation Bio (NYSE: NUVB) will present four posters on safusidenib, its investigational mutant IDH1 inhibitor, at the Society for Neuro-Oncology (SNO) Annual Meeting in Philadelphia on November 12-15, 2026. One poster carries updated long-term Phase 2 J201 results that go beyond the topline data the company announced in July 2026.

SYDNEY – November 02, 2026 -- Kazia Therapeutics (NASDAQ: KZIA) will present two preclinical abstracts on its lead asset paxalisib at the San Antonio Breast Cancer Symposium (SABCS), held Dec. 8-11, 2026, in San Antonio, Texas.